Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Medplus Health Services' subsidiary, Optival Health Solutions Private Limited, received a drug license suspension order from the Assistant Director, Drugs Control Administration, Siddipet, Telangana. The suspension is for four days and applies to a single store located at Main Road, Bichkunda, Telangana. The order was received on August 21, 2025, and was issued under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of approximately Rs. 0.77 lacs from this action. The disclosure is being made under SEBI Listing Regulations to keep stock exchanges informed.
The financial impact is negligible at roughly Rs. 0.77 lacs in potential revenue loss, limited to a single store for four days, and is unlikely to materially affect the company's overall operations or stock price.